[Therapy with glucose-insulin-potassium reduces the complications in the acute phase of myocardial infarct. Arguments against].
Glucose-insulin-potassium therapy has shown its efficacy in diminishing the myocardial damage under ischemia-reperfusion conditions in experimental models. This effect appears to be mainly due to the increase of anaerobic glycolysis in ischemic cells with a consequent reduction in the use of fatty acids. On the other hand, clinical studies in the acute phase of myocardial infarction are out-dated and almost non-existent in the thrombolytic era. The absence of current consistent data makes it difficult to draw conclusions concerning the real utility of this therapy in the clinical practice.
Arós
F
F
Servicio de Cardiología, Hospital Txagorritxu, Vitoria-Gasteiz.
Loma-Osorio
A
A
D000818:Animals; D002314:Cardioplegic Solutions / Q000378:metabolism / Q000627:therapeutic use*; D005227:Fatty Acids / Q000378:metabolism; D005947:Glucose / Q000378:metabolism / Q000627:therapeutic use; D006801:Humans; D007328:Insulin / Q000378:metabolism / Q000627:therapeutic use; D009203:Myocardial Infarction / Q000378:metabolism / Q000628:therapy*; D009206:Myocardium / Q000378:metabolism; D011188:Potassium / Q000378:metabolism / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D017211:Treatment Failure
D002314:Cardioplegic Solutions; D005227:Fatty Acids; D007328:Insulin; C030396:glucose-insulin-potassium cardioplegic solution; D005947:Glucose; D011188:Potassium